Transforming growth factor β , (TGFβ) secreted by immunogenic ex vivo human carcinoma cells, counteracts the activation and inhibits the function of autologous cytotoxic lymphocytes. Pretreatment with interferon γ and tumor necrosis factor α reduces the production of active TGFβ

MLA

Farkas Vánky, and Noémi Nagy. “Transforming Growth Factor β , (TGFβ) Secreted by Immunogenic Ex Vivo Human Carcinoma Cells, Counteracts the Activation and Inhibits the Function of Autologous Cytotoxic Lymphocytes. Pretreatment with Interferon γ and Tumor Necrosis Factor α Reduces the Production of Active TGFβ.” Cancer Immunology, Immunotherapy, vol. 45, Jan. 1998, pp. 306–12. EBSCOhost, https://doi.org/10.1007/s002620050447.

APA

Farkas Vánky, & Noémi Nagy. (1998). Transforming growth factor β , (TGFβ) secreted by immunogenic ex vivo human carcinoma cells, counteracts the activation and inhibits the function of autologous cytotoxic lymphocytes. Pretreatment with interferon γ and tumor necrosis factor α reduces the production of active TGFβ. Cancer Immunology, Immunotherapy, 45, 306–312. https://doi.org/10.1007/s002620050447

Chicago

Farkas Vánky, and Noémi Nagy. 1998. “Transforming Growth Factor β , (TGFβ) Secreted by Immunogenic Ex Vivo Human Carcinoma Cells, Counteracts the Activation and Inhibits the Function of Autologous Cytotoxic Lymphocytes. Pretreatment with Interferon γ and Tumor Necrosis Factor α Reduces the Production of Active TGFβ.” Cancer Immunology, Immunotherapy 45 (January): 306–12. doi:10.1007/s002620050447.